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Abstract
Historical data from previous clinical trials, observational studies and health records
may be utilized in analysis of clinical trials data to strengthen inference. Under the
Bayesian framework incorporation of information obtained from any source other than
the current data is facilitated through construction of an informative prior. The ex-
isting methodology for defining an informative prior based on historical data relies on
measuring similarity to the current data at the study level that can result in discarding
useful individual patient data (IPD). This paper proposes a family of priors that utilize
IPD to empower statistical inference. IPD-based priors can be obtained as a weighted
likelihood of the historical data where each individual’s weight is a function of their
similarity to the current study population. We demonstrate that the proposed prior
construction approach can considerably improve estimation accuracy and precision in
compare with existing methods.
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1 Introduction
The use of historical data to strengthen statistical inference appears in various settings
and applications. A few examples are analysis of clinical trials data where information is
available from observational studies, meta-analysis, and analysis of social survey results with
information borrowed from other sources such as the census (Golchi, 2017). The focus of the
present paper is informed analysis of clinical trials using external data sources. However,
the proposed methodology can be well adapted to other settings.
Use of historical data or data from any external source other than the concurrent study
has become essential in many clinical trials. Common scenarios include trials where required
sample sizes are infeasible to collect. Sample size restriction can be either due to scarcity of
the eligible population (rare diseases) or small effect sizes that are clinically meaningful but
require larger than feasible study sizes to achieve statistical significance. Another interesting
family of studies consists of trials where a control cohort is completely or partially absent for
ethical or practical reasons. Single arm phase I or II trials have become popular in oncology
and drug development; the analysis of these trials require effective and robust statistical
methodology in utilizing past studies.
Under the Bayesian framework, information from any source other than the study data
are incorporated via the prior distribution. A variety of approaches have been proposed
in the literature for construction of informative priors based on historical data. One of the
most popular methods is referred to as power priors. Introduced formally by Chen & Ibrahim
(2000), power priors are based on a weighted log-likelihood of the historical data. The role
of the weight (or power) is to control the level of contribution of past studies to inference.
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Various methods have been proposed for specification of the power(s). For a comprehensive
review of theory and application of power priors see Ibrahim et al. (2015).
Another popular method for taking advantage of historical and external data is via a
hierarchical modeling approach that treats the parameters of the concurrent and historical
studies as random effects with a common mean and variance. This approach and its vari-
ations are referred to by various terms including commensurate priors, dynamic borrowing
and meta-analytic predictive priors. Examples of work on this family of priors include Hobbs
et al. (2012); Schmidli et al. (2014); Rover & Friede (2019); Lewis et al. (2019) and Weber
et al. (2019) that introduces an R package implementing it. In addition, Chen & Ibrahim
(2006) study the relationship between power priors and priors based on hierarchical model-
ing. Finally, Hong et al. (2018) consider power and commensurate priors for synthesizing
aggregate and IPD in a network meta-analysis (NMA) framework. However, information
borrowing is decided at the study level rather than at the individual level.
While both above mentioned methods are powerful tools, they have a common short-
coming. The amount of information incorporated into the prior from external data sources
depends on the overall legitimacy of the study as a source of information. Under the power
prior approach, for example, each study is given a power based on its similarity to the con-
current study. Commensurate priors are even less forgiving of heterogeneity of historical
studies since the amount of information borrowed is determined by the variability among
the studies. As a result, less information is used from all of the studies even if some of them
strongly resemble the concurrent data. In other words, the gap in the literature on prior
construction from historical data is in utilizing individual patient data (IPD).
Consider, for example, the hypothetical scenario presented in Figure 1. The study pop-
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ulation of the concurrent study Sc is the target population. Among the three available
historical studies, the first one S1 is assumed to have the same study population as the con-
current study and is, therefore, fully exchangeable with the concurrent study. The second
study S2 is a sample of a hypothetical population, B, that has a negligible overlap with the
target population. This means that there may be individuals in S2 whose characteristics
match the target population but the majority of individuals do not belong to the target pop-
ulation. The hypothetical population, A, on the other hand, contains the target population
– for example is defined based on a wider age range of patients. Therefore, S3 is expected
to have a significant overlap with the concurrent study but there are individual patient data
under S3 that should not be included in the inference.
Currently, no method of prior construction exists that allows the researcher to use a
portion of historical IPD. Under the existing approaches, a measure of similarity or target
population membership is explicitly (power priors) or implicitly (commensurate priors) esti-
mated at the study level rather than the individual level. This results in loss of potentially
useful information in cases where the study populations have some but not complete overlap.
In this paper we propose an approach for construction of informative priors from historical
data that aims at using individual patient data. We generalize the power prior framework
such that every individual within the historical studies is assigned a distinct power (or
weight). The powers are specified with respect to a distance measure to the target population.
Assuming that the concurrent trial sample is the closest proxy for the target population, this
distance measure is estimated according to the similarity of individuals to the concurrent
study sample. The data-prior conflict is dealt with via eliminating historical IPD that fall
outside a credible set defined based on the distribution of the similarity measures within the
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concurrent study.
The remainder of the paper is organized as follows: A motivating example is presented
in Section 2. The proposed methodology is described in Section 3. Section 4 follows with
a simulation study where the proposed method is compared to existing prior construction
methods. The proposed approach is applied to the motivating example in Section 5 and
finally a discussion follows in Section 6.
2 Motivating Example
As a motivating example consider four trials in second line non-small cell lung cancer
(NSCLC) with sufficiently similar patient population and the common primary outcome
of overall survival: INTEREST (Douillard et al. , 2010), ZODIAC (Herbst et al. , 2010),
PROCLAIM (Senan et al. , 2016) and Study 57 (Natale et al. , 2011). All trials were
conducted for participants who had previously been treated for NSCLC. The IPD data for
these studies was acquired from Project Data Sphere (http://www.projectdatasphere.com),
an open-source repository of individual-level patient data from oncology trials. A brief sum-
mary of key trial characteristics for the included trials is provided in Table 1.
Patients within INTEREST, ZODIAC and Study 57 were predominantly stage IV, how-
ever PROCLAIM exclusively recruited stage III patients (of which 52% were stage IIIB).
This is reflected in the control group median survival time which was between 8-10 months
for all trials except for PROCLAIM that demonstrated a median survival time of 25 months
(Figure 2a).
Other differences between studies included exposure to prior therapy. Whilst all included
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patients had previously received at least one previous chemotherapy regimen, the proportion
of patients who had received two or more varied between 0 (PROCLAIM, ZODIAC) to 35%
(Study 57). Similarly, radiotherapy varied significantly, with PROCLAIM being the only
trial which permitted (concurrent) chemoradiotherapy. Other patient characteristics were
largely well balanced between groups, with an average age of 60 ± 1 years, and a majority
of patients (54-75%) having adenocarcinoma histology.
Consider the hypothetical scenario that ZODIAC is the “concurrent” trial and we are
interested in using data from the other three clinical trials to enrich the control arm with the
hope of improving inference and achieving more power. Given the brief description of the four
trials provided above, PROCLAIM is substantially different that the three other trials and
should not be used to inform the inference. Suppose, however, that the above-mentioned
differences were not reported and/or were not visible from data visualization. Figure 2b
shows Bayesian point estimates (posterior mean) and 95% credible intervals for the hazard
ratio in ZODIAC obtained with no prior (NP), using the full control data from the other
three trials with the same weight as the concurrent data (FH), using power priors (PP) and
commensurate priors (CP) and the proposed approach (TIW) that is described in the next
section. It is clear that blindly using any available data can mislead the analysis: FH results
in credible intervals including 1 while analysis of ZODIAC data alone yields significance in
favour of the treatment. PP and CP result in almost identical results as NP since historical
study heterogeneity results in minimal amount of borrowing from past data under these
methods. TIW however results in smaller HR estimates with higher precision as a result of
using individual patient data that closely resemble the ZODIAC study population.
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3 Methodology
While the focus of the present work is on using historical controls for analysis of clinical
trials, the proposed method can be generally applied to Bayesian inference. In fact, the
distinction between the control and treatment arm data in clinical trials is not necessary
to the approach and would only complicate the notation. Therefore, in the following, the
methodology is explained in a general inference framework.
Consider a (concurrent) study that is designed to estimate a set of parameters, θ , based
on sample data Sc = (S1,c, . . . , SNc,c) where Sn,c indicates all the available data on subject
n in the concurrent study and Nc is the concurrent study sample size. Suppose that H
historical studies are available whose data may be used to improve the inference. The data
of each historical study h = 1, . . . , H are denoted by Sh = (S1,h, . . . , SNh,h) where Nh denotes
the sample size of each historical study data. The likelihood is denoted by
pi(Sc | θ) =
Nc∏
n=1
pi(Sn,c | θ).
Bayesian inference may be performed using only the concurrent study data via the posterior
distribution of the parameters given the concurrent study data,
piNP (θ | Sc) ∝ pi0(θ)pi(Sc | θ),
where pi0(θ) is a non-informative prior distribution.
At the other end of the spectrum of using historical data the following informative prior
assigns equal weight to the past and present data,
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piFH(θ) ∝ pi0(θ)
H∏
h=1
pi(Sh | θ) = pi0(θ)
H∏
h=1
Nh∏
n=1
pi(Sn,h | θ).
This approach can significantly mislead the inference since past studies are commonly differ-
ent than the concurrent study in various aspects and conclusions drawn from past data most
often cannot be immediately generalized to the target population. In addition, the prior can
overpower the likelihood in cases of prior-data conflict.
As an alternative, we propose the following individually weighted prior
piIW (θ) ∝ pi0(θ)
H∏
h=1
Nh∏
n=1
pi(Sn,h | θ)ωn,h . (1)
where the weights ωn,h are specified such that subjects who are considered “eligible” under
the concurrent study population will receive a larger weight.
While piIW (θ) moderates the amount of information contained in the prior, there is still
risk of overpowering the likelihood. A large number of conflicted data with small weights
can result in sufficient information to bias the inference. Therefore we propose to use only
the portion of the IPD with corresponding weights above a specific threshold,
piTIW (θ) ∝ pi0(θ)
H∏
h=1
Nh∏
n=1
pi(Sn,h | θ)ωn,h1(ωn,h>ρ). (2)
The main challenge is to define the power ωn,h such that they meaningfully represent eligi-
bility under the target population. Stuart et al. (2001) used propensity scores to measure
generalizability of clinical trial results. However, propensity scores do not capture complex
data structure including non-linearity. In the following we address this issue and provide an
intuitive approach for specifying the truncation threshold, ρ.
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3.1 Specification of the weights
We propose two methods for specifying the individual weights in the likelihood according
to the types of available data. The first method is based on the distance of each individual
to the target population that is estimated by the Mahalonobis distance of the individual
to the concurrent study distribution. The Mahalanobis distance is a simple and reliable
dissimilarity measure as long as all the variables are continuous and their joint distribution
can be characterized by a mean vector and a covariance matrix. The second method is to
specify the weights as the posterior predictive probability of each historical patient data
given the present data. This posterior predictive probability is computed based on a model
that captures important features of the data but is not necessarily the same as the analysis
model. We refer to it as the similarity model.
3.1.1 Mahalanobis distance
The powers ωn,h should be specified such that subjects who better fit the target population
receive larger weights. Considering the concurrent study as the most representative sample
of the target population, the weight of every patient in historical studies is specified as a
function of their Mahalanobis distance to the concurrent study sample. The Mahalanobis
distance is defined based on the joint distribution of all the common variable among studies,
i.e, response and covariates, characterized by a mean vector and a covariance matrix. The
only underlying assumption is that all variables are continuous.
Let Sn,h denote the vector of all (continuous) variables including covariates and response
for patient n in historical study h. The distance of patient n, h to the target population is
estimated as
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dn,h =
√
(Sn,h − µ)TΣ−1(Sn,h − µ),
where µ and Σ are the sample mean vector and covariance matrix of the concurrent study.
The weights are then obtained as follows
ωn,h = 1− G(dn,h),
where G maps d monotonically onto (0, 1),
G(dn,h) = dn,h −maxn dn,h
maxn dn,h −minn dn,h .
Note that the minimum and maximum of the Mahalanobis distances used in the mapping
are taken across all calculated distances for all the available data including those of the
concurrent study.
With this definition using the information of subjects whose weights are larger than
a given threshold ω0 is equivalent to selecting the subjects whose distance to the target
population is within a certain threshold,
ωn,h > ω0 ⇐⇒ dn,h < G−1(1− ω0) .= δ0,
where δ0 can be specified as a quantile of the distribution of the Mahalanobis distances within
the concurrent study. For example if δ0 is the 95% quantile of the distance distributions,
any historical individual patient data that demonstrates characteristics that fall outside the
centre 95% of the concurrent study data distribution is discarded from the prior.
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3.1.2 Similarity model
The Mahalanobis distance is not appropriate as a dissimilarity measure when discrete vari-
ables are present. Generalizations of the Mahalanobis distance have been proposed in the
literature for mixed discrete and continuous variables (Barhen & Daudin, 1995; Bedrick et al.
, 2000; de Leon & Carrie`re, 2005). The generalized distances are based on models over the
joint distribution of variables, namely modeling nominal variables according to a multinomial
distribution and assuming multivariate Gaussian distributions for the continuous variables
under each level (or level combination) of the nominal variables.
Similarly, we propose a model-based approach for cases with a mix of discrete and contin-
uous variables. However, instead of defining a distance measure that needs to be converted
into a similarity measure, we use the posterior predictive probability of the historical data
given the concurrent data as the similarity measure. Note that the model which the pre-
dictive probability is based upon is not necessarily the same as the analysis model in that
all the variables (including covariates) are assumed to follow a probability distribution. The
reason is that joint modelling of all the existing variables is crucial for calculating a similar-
ity measure that reflects patient/study differences while in most clinical trial data analysis
covariates are treated as fixed. Moreover, the similarity model does not have to provide the
best fit to the data and therefore can be simpler than the analysis model. For example, one
could model all continuous variables as Gaussian random variables for measuring similarity
despite presence of non-Gaussian features in the data.
Consider the joint similarity model of a set of variables represented by S is denoted by
pi(S | ψ), (3)
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where ψ is the vector of model parameters. Note that ψ is generally not identical to θ since,
as mentioned above, the similarity model is not the same as the analysis model. However,
ψ and θ may have common components.
The weight ωn,h is then obtained as the posterior predictive density of patient n in study
h given the concurrent study data,
pi(Sn,h | Sc) =
∫
pi(Sn,h | ψ)pi(ψ | Sc)dψ, (4)
which is estimated by Monte Carlo. Given a sample {ψn}Nn=1 from pi(ψ | Sc) by fitting (3)
to Sc we have,
pˆi(Sn,h | Sc) = 1
N
N∑
n=1
pi(Sn,h | ψn). (5)
The weights are then obtained by mapping this posterior predictive probability estimate
onto (0, 1),
ωˆn,h = G(pˆi(Sn,h | Sc)). (6)
Similar to what was explained for the Mahalanobis distance method, the truncation threshold
is obtained as a quantile of the weights in the concurrent study.
4 Simulation study
In this section we make comparisons between the proposed IPD-weighted prior and the
existing approaches for borrowing historical information that were discussed in Section 1.
At each iteration of the simulation, data for a concurrent clinical trial and four historical
studies are generated from a Gaussian likelihood,
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yc ∼ N (βxc + θz, σ2),
where yc is the vector of responses for the concurrent trial that is of size, Nc = 1000; xc is
a continuous covariate vector of size Nc; β denotes the covariate effect; z is the vector of
arm allocation indicators that is generated from a Bernoulli(0.5) distribution where zn = 1
shows that subject n is assigned to the treatment arm and zn = 0 represents control arm
assignment; and θ is the parameter of interest that represents the treatment effect and its
value for the simulations is fixed at θ = 2.
Data for the control arms of historical studies are generated as follows:
yh ∼ N (δh + βxh, σ2), h = 1, . . . , 4,
where yh are vectors of size Nh = 500, δh are the study effects that are fixed at δ =
(0, 0, 1,−.5) for the four studies meaning that the control data from the first two historical
studies are exchangeable with the concurrent trial control arm while there are unmeasured
variables or unreported differences between the last two historical studies and the concurrent
trial that shift the mean responses.
The observation error follows a normal distribution with variance 0.01 across all studies.
The covariates for the concurrent and historical studies are generated in the following manner
to represent overlapping structure of the study populations,
xc,x2 ∼ N (10, 1); x3 ∼ N (15, 1) x1,x4 ∼ 1
3
N (15, 1) + 2
3
N (10, 1).
Bayesian analysis is then performed using priors that are constructed by the proposed method
and the other existing methods. More specifically, the following model is fit to each data set
simulated using the above procedure,
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pi(θ, β0, β, σ
2 | y) ∝ pi0(θ, β0, β, σ2)
H∏
h=1
Nh∏
n=1
φ(yn,h | β0 + βxn,h, σ2)ωn,h
Nc∏
n=1
φ(yn | β0 + βxn + θzn, σ2), (7)
where pi0(θ, β0, β, σ
2) is an independent non-informative prior and φ(. | a, b2) denotes the
Gaussian probability density function with mean a and variance b2. The weights ωn,h are
given for each of the competing methods for prior construction as follows,
No prior: The historical controls are not used in analysis of the concurrent trial, i.e.,
ωn,h = 0, ∀n, h;
Full history prior: The historical controls are fully combined with the concurrent study
controls, i.e., ωn,h = 1, ∀n, h;
Power prior: Each historical study is assigned a weight according to the similarity to
the concurrent trial
ωn,h = ωh =
1
Nh
Nh∑
n=1
(1− G(dn,h)) h = 1, . . . , H.
Truncated power prior: Similar to power priors but the weights are truncated such
that only the historical studies that are similar enough to the concurrent study are used;
ωh =

1
Nh
∑Nh
n=1 (1− G(dn,h)) if 1Nh
∑Nh
n=1 (1− G(dn,h)) > ρ
0 if 1
Nh
∑Nh
n=1 (1− G(dn,h)) < ρ,
where
ρ = Q0.95(1− G(dn,c)).
Individually weighted prior: Using historical controls with each individual weighted,
i.e., ωn,h = 1− G(dn,h) for n = 1, . . . , Nh, h = 1, . . . , H.
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Truncated individually weighted prior: Similar to the individually weighted ap-
proach but including individuals from the historical study who have a sufficiently high pos-
terior predictive probability of being included in the concurrent study;
ωh =

1− G(dn,h) if 1− G(dn,h) > ρ
0 if 1− G(dn,h) < ρ.
Note that using the Mahalanobis distance and the posterior predictive probability for the
weights ωn,h are equivalent for this simulated example since y and x can be modelled by the
Gaussian distribution.
Commensurate prior: The commensurate prior is the only prior that cannot be de-
scribed by the general model in (7),
piCP (θ, δs, β, σ
2, µδ, τ | yc,yh) ∝ pi0(µδ, τ 2,θ, β, σ2)
5∏
s=1
φ(δs | µδ, τ 2)
4∏
h=1
Nh∏
n=1
φ(yn,h | δh+1 + βxn,h, σ2)ωn,h
Nc∏
n=1
φ(yn | δ1 + βxn + θzn, σ2),
where µδ and τ
2 are the common mean and variance of the study random effects. The
variance τ 2 is the key parameter that controls the amount of information borrowed according
to the study heterogeneity. Note that the commensurate prior is in fact the “correct” model
as it captures the data generative mechanism.
The methods are compared in terms of the root mean squared error,
RMSE =
1
K
K∑
m=1
(θk − θT )2,
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where θk is the k
th draw of the posterior and K = 2000 is the number of draws. The
distribution of the RMSE over the simulation iterations are plotted in Figure 3.
It is not surprising that using the full historical controls with equal weights as the con-
current trial control data (FH), or weighted either individually (IW) or at the study level
(PP) result in the highest RMSE among the compared methods (Figure 3a). Any contribu-
tion from the non-exchangeable portion of the historical data can result in estimation bias
(Figure 3b). It is, however, interesting that the commensurate prior (CP) results in almost
as large RMSE as FH, IW and PP. When looking at bias and estimation variance, it becomes
clear that CP yields unbiased estimates, however, the estimation variance is the highest due
to the hierarchical modelling structure that translates the heterogeneity in historical data
into estimation variance. The truncated power prior (TPP) and the truncated individually
weighted (TIW) prior result in smallest estimation errors. TIW results in slightly lower
RMSE as it takes advantage of more individual patient data and therefore yields more pre-
cise estimates. The improvement by TIW over TPP is expected to be more visible when
more studies with partially overlapping populations with the target population are available.
5 Analysis of the NSCLC data
In this section the proposed methodology is applied to the data introduced in Section 2.
ZODIAC is considered as the concurrent trial and the other three studies are used to enrich
the control arm. As mentioned earlier, one of the three historical trials (PROCLAIM) showed
significantly different patient and survival characteristics. Dron et al. (2019) showcase
analysis of these studies using the commensurate prior approach with different levels of
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borrowing arising from including/excluding PROCLAIM among the historical studies. Given
the clear differences in eligibility criteria and control arm definition, this trial should be
excluded from the set of historical studies. However, we keep this study among the historical
studies to demonstrate that the proposed method can be used to automatically exclude
ineligible historical data.
Since the data includes a number of discrete covariates such as sex and race, for speci-
fication of the weights in the individually weighted prior, we use the proposed model-based
approach. In the following, we introduce the similarity model as well as the model used for
Bayesian analysis of the ZODIAC trial.
In this historical controls approach the similarity model is used only to model the con-
trol arm data. The outcome is time of death for observed events and the time of lost to
follow-up for patients with censored data. Available covariates among all four studies in-
clude age (treated as continuous), sex (dichotomous) and race with four categories that was
reconstructed as three dummy variables. Denoting the outcome of patient n in the control
arm by yctrln , the censoring variable by ν
ctrl
n and vector of covariates by x
ctrl
n , the similarity
model is defined as follows,
yctrln ∼ N (µyn, σ2y), νctrln ∼ Bernoulli(pν),
xctrl1,n ∼ N (µx, σ2x), xctrl2:4,n ∼ Bernoulli(px)
where xctrl1,n is the first component of x
ctrl
n , i.e. age and x
ctrl
2:4,n is the vector of dichotomous
covariates, i.e., sex and race categories; and
µyn = β
Txctrln + ν
ctrl
n η1 + (1− νctrln )η2.
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All the continuous parameters and hyper-parameters (i.e., β, η1, η2, µx) are assigned vague
normal priors with mean zero and variance 106; probability parameters, pν and the vector
px are assigned uniform priors; and the variance parameters, σ
2
y and σ
2
x are assigned half-
Cauchy (truncated to exclude negative numbers) distributions with mean zero and variance
106 as prior. The similarity model is fit to the IPD control data from the concurrent study
(ZODIAC) that is denoted by (yctrlc ,X
ctrl
c ,ν
ctrl
c ). The weight for each individual within the
control arms of the historical studies is calculated using (6),
ωˆn,h = pi(y
ctrl
n,h ,x
ctrl
n,h , ν
ctrl
n,h | yctrlc ,Xctrlc ,νctrlc ).
The analysis model is defined as a Bayesian hierarchical model with the proportional
hazards assumption that is used to analyse the survival data (control and intervention arms)
of the concurrent study. More specifically the likelihood is given by
pi(y | α, λn) =
NC∏
n=1
f(yn | α, λn)νnS(yn | α, λn)(1−νn),
where y is the vectors of responses, f(yn | α, λn) is a Weibull probability density function
with shape parameter α and scale parameter λn, S(yn | α, λ) is the Weibull survival function,
and νn = 0 indicates that patient n is right-censored. The regression model is embedded
within the scale parameter,
λn = δ + xnβ + anθ,
where an = 1 indicates treatment assignment. The parameter of interest is θ which represents
the treatment effect. The hazard ratio is given as,
HR = exp (θ).
The IPD-based prior is defined as follows,
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piTIW (α,β, δ, θ) = pi0(α,β, δ, θ)
H∏
h=1
Nh∏
n=1
[f(yn,h | α,β, δ)νn,hS(yn,h | α,β, δ)(1−νn,h)]ωˆn,h(1−an,h),
where pi0(α,β, δ, θ) is an independent uninformative prior. Specifically, δ, β and θ are as-
signed normal distributions centered at zero with variance 106 and α, is assigned the same
normal distribution truncated at zero since α > 0. The power (1 − an) indicates that only
control arm historical data are incorporated into the prior. Note that the informative prior
does not contain information about θ since it only uses historical data from the control arm.
The posterior kernel is then given as the product of the prior and the likelihood,
pi(α,β, δ, θ | y) ∝ piTIW (α,β, δ, θ)pi(y | α, λn(β, δ, θ)).
Samples are drawn from the above posterior distribution using Markov chain Monte Carlo.
The data of the ZODIAC trial are analysed using the proportional hazards Weibull model
with and without an informative prior that is constructed using the proposed approach
based on the other three trials. Figure 4 shows a summary of results obtained from the two
methods. Specifically, figure 4a shows the Kaplan-Meier curves for the data from ZODIAC
trial, figure 4b shows the estimated survival curves for the control and treatment arms
obtained with no prior (top panel) and the individually weighted prior (bottom panel). A
larger gap between the survival curves in the bottom panel is the result of incorporating
additional control information included from the historical data. With respect to the effect
estimates this translates into an estimated hazard ratio that is 25% smaller with narrower
credible intervals (figure 4c).
Considering the between study differences and specially the fact that PROCLAIM stands
out among the three historical trials as one that should not be used to inform inference, it
is interesting to see what percentage of individual patient data from each historical trial
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is incorporated into the prior. Figure 5 shows the distribution of raw powers for the four
studies. The vertical line shows the truncation point which is specified as the 5% quantile
of the power distribution for ZODIAC, i.e., 95% of individuals within the control arm of
ZODIAC trial have powers greater than this threshold. Note that all individuals within
ZODIAC will be included in the analysis model with power one. For the other three trials,
Study57 contributes most to the prior with 97% of powers above the cut-off value, followed
by INTEREST with 82% of IPD contributing to the prior with their corresponding weights
and last is PROCLAIM with only 34% of powers greater than the threshold. In fact, the
majority of posterior predictive probabilities are zero for PROCLAIM representing the non-
exchangeability of this study with the concurrent study.
6 Discussion
In this article we have proposed methodology for incorporating individual patient data from
past studies to the analysis of clinical trial data with the goal of improving statistical infer-
ence. The proposed family of priors can be considered a generalization of power priors where
instead of assigning a power to study each individual within the historical studies receives
a power. The weight or power assigned to each individual is a function of their similarity
to the concurrent study population. The similarity is measured through a set of available
variables including covariates and outcome(s) that are shared among the past and present
studies. The Mahalanobis distance for continuous data and a general model-based approach
that suits any data type are recommended for specification of the weights.
The general weight specification approach relies on a similarity model that is intended
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to capture important data structure including correlations among variables. We emphasize
that the similarity model is not necessarily identical to the analysis model. It can be more
complex in that it assigns probability distributions to covariates that may be considered fixed
under the analysis model. But it can be simpler in that approximate Gaussian distributions
may be used even when data are not entirely Gaussian.
In our simulation studies we did not observe any significant difference in the results from
using a similarity model that is exactly the data generating model versus one that assumes an
approximate Gaussian distribution for all continuous variables. However, as non-Gaussian
features become more dominant in the data, a similarity model that captures these features
can result in more appropriate information borrowing.
An essential component of the proposed prior construction approach is a cut-off value for
the powers and discarding individual patient data whose powers fall below this cut-off value.
The truncation is introduced to avoid prior-data conflict. The intuitive explanation is that
any individual data from the historical studies that fall outside a pre-specified credible set
of the concurrent study distribution should not be used to inform inference.
A question that remains open is how to select the variables to be included in the similarity
model. This is not a serious issue in the NSCLC application included in the present work since
the covariates consist of a small number of demographic variables that can be reasonably used
to define the study population. However, in cases where there are a large number of shared
covariates among studies it is important to select a subset of variables that meaningfully
characterize the target population.
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Data and Code
The IPD under the control arm for the four NSCLC trials was obtained from Project Data
Sphere (http://www.projectdatasphere.com), an open-source repository of individual-level
patient data from oncology trials. No IPD was available under the intervention arms of
either trials. Therefore, we recovered IPD for the intervention arm of ZODIAC by digitizing
the Kaplan-Meier curves provided in the publication.
All the Bayesian computation, i.e., posterior sampling, was performed in RStan. The
Stan models together with the R script that can be used to reproduce the results of the
paper are provided at https://github.com/sgolchi/IPD prior.
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INTEREST ZODIAC PROCLAIM Study 57
Control group median
overall survival
(months)
8 10 25 7.8
Stage III, (%) 38 15 100 17
Stage IV, (%) 53 85 0 83
Average age (years) 60.5 59 59 61
Adenocarcinoma
histology (%)
54 60 75 60
Two or more prior
chemotherapy
regimens (%)
16 0 0 35
Radiotherapy
sequence, dose
(control arm)
None None
60-66Gy,
Concurrent
None
Table 1: Summary of key trial characteristics for the four NSCLC trials
Figure 1: Hypothetical example representing partially overlapping study populations.
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(a) (b)
Figure 2: (a) Overall survival distribution for the four NSCLC trials (b) Bayesian 95% credible
intervals for the hazard ratio for ZODIAC obtained by no prior (NP), truncated individually
weighted prior (TIW), commensurate prior (CP), power prior (PP) and full historical data
(FH).
(a)
(b) (c)
Figure 3: Simulation results: (a) RMSE, (b) bias, and (c) length of 95% credible intervals
for the seven methods: full history prior (FH), individually weighted prior (IW), power prior
(PP), commensurate prior (CP), no prior (NP), truncated power prior (TPP) and truncated
individually weighted prior (TIW).
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(a) (b)
(c)
Figure 4: Analysis of ZODIAC trial data (a) Kaplan-Meier curves (b) Survival curves obtained
from the Weibull model with no historical data (top panel) and the individually weighted
historical data prior (bottom panel) (c) Bayesian point estimates (posterior mean) and 95%
credible intervals for the hazard ration resulted from the no-prior and TIW-priors.
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Figure 5: Raw power distribution for the four NSCLC trials.
29
